Japan
Heartseed Enters into induced Pluripotent Stem Cell Purification Patent License Agreement for Commercialization of Cell Therapy
Aiming at contributing to the industrialization of iPSC-based therapies in areas other than the heart by out-licensing our proprietary platform technology "Metabolic Selection"
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, and Fuji Pharma Co., Ltd. (“Fuji”) (TSE: 4554), a pharmaceutical company specializing in development, manufacture and marketing in the fields of women’s healthcare and acute medical care, today announced they have entered into a time-limited (up to approximately eighteen months) agreement to negotiate exclusively with each other regarding a potential license to develop and commercialize Vistagen’s PH80 in Japan
Ono Pharmaceutical Enters into Drug Discovery Collaboration Agreement with Twist Bioscience
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a drug discovery agreement with Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) to discover and develop novel antibodies for the treatment of autoimmune diseases.
Mitsui to expand health startup investment with focus on ASEAN
Japanese trading house Mitsui & Co. plans to increase fivefold its investments in medical startups over the next three years, with a focus in Southeast Asian companies.
BionicM Earns FDA Registration and Class II Exempt Device Listing for Bio Leg™; Its New Motor-Robotic Prosthetic Knee
BionicM, an innovative Japanese medical device startup, is pleased to announce that it has received U.S. Food and Drug Administration (FDA) 510(k) exemption registration for Bio Leg™; its robotic prosthetic knee.
Japanese and Chinese Healthcare Companies Dominate in Asian Capital Market
A review of the top 25 Healthcare companies in Asia-Pacific
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida’s Commitment to Redefining Cancer Cell Therapy
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, CEO: Mark Gergen, "Poseida") today announced a strategic investment to support the advancement of Poseida's commitment to redefining cancer cell therapy.
Astellas to Open New Life Sciences Facility in DivcoWest’s Cambridge Crossing Neighborhood
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and DivcoWest, a DivCore Capital Company, announced today plans for Astellas to open a new state-of-the-art life sciences facility at 441 Morgan Avenue, in the Cambridge Crossing (CX) neighborhood in Cambridge, Mass.
Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732
Sosei Group Corporation (“the Company”; TSE: 4565), the world-leader in GPCR-focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world’s largest independent funder of cancer research, today announce that the first patient has been dosed in a Phase I/IIa clinical trial evaluating Sosei Heptares’ orally available small molecule cancer immunotherapy drug HTL0039732 for advanced solid tumors.
Meiji Seika Pharma Announces Positive Results in Phase II Study of ME3183, a Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis in the United States and Canada
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced that ME3183, a novel highly-potent selective phosphodiesterase-4 (PDE4) inhibitor, met the primary endpoint based on “PASI-75”, defined as the proportion of subjects achieving 75% improvement in Psoriasis Area Severity Index (PASI), in phase II clinical trial in patients with moderate-to-severe plaque psoriasis conducted in the United States and Canada.
